AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32423239
Drug: SHP465 MAS
RxNorm normalized name: Zhi ma oil
DrugBank: Sesame oil (DB11172)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHP465 MAS (25, 50, or 75 mg)
Trial: 35276662
Drug: Training Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training Group (TG) - variable practice training with weighted wrist bands, twice a week for 1 month
Trial: 36346079
Drug: Bepirovirsen 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepirovirsen 300 mg weekly for 24 weeks (group 1)
Trial: 36346079
Drug: Bepirovirsen 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepirovirsen 300 mg for 12 weeks then 150 mg for 12 weeks (group 2)
Trial: 36346079
Drug: Bepirovirsen 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepirovirsen 300 mg for 12 weeks then placebo for 12 weeks (group 3)
Trial: 36346079
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 12 weeks then Bepirovirsen 300 mg for 12 weeks (group 4)
Trial: 36346079
Drug: Bepirovirsen 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepirovirsen 300 mg weekly for 24 weeks
Trial: 32729802
Drug: Inoculated with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inoculated with 10 μL of zoospore suspension (2 × 105 zoospore/ml)
Trial: 33030064
Drug: Drug adjustment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug adjustment
Trial: 33876439
Drug: Chronic use
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic use of RAAS blockers
Trial: 33876439
Drug: Non-use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-use of RAAS blockers
Trial: 32610608
Drug: Leucine-Enriched Amino
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine-Enriched Amino Acid Supplement with breakfast
Trial: 32610608
Drug: Leucine-Enriched Amino
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine-Enriched Amino Acid Supplement post-exercise
Trial: 32548951
Drug: Exposure-long (EXP-L)
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure-long (EXP-L)
Trial: 32548951
Drug: Exposure treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure treatments (EXP)
Trial: 36039506
Drug: Individual cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual cognitive processing therapy (CPT)
Trial: 36039506
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive processing therapy (CPT)
Trial: 34034897
Drug: Implant-retained removable
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implant-retained removable dentures
Trial: 34363999
Drug: Antidepressant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant treatment (3 commonly prescribed antidepressants)
Trial: 34604936
Drug: Laser-microgrooved implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser-microgrooved implants with laser-microgrooved prosthetic abutments
Trial: 34604936
Drug: Laser-microgrooved implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser-microgrooved implants with machined prosthetic abutments
Trial: 33975553
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist protocol (fresh transfer cycles)
Trial: 33975553
Drug: Depot GnRH
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Depot GnRH agonist protocol (fresh transfer cycles)
Trial: 33975553
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist protocol (frozen-thawed transfer cycles)
Trial: 33975553
Drug: Depot GnRH
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Depot GnRH agonist protocol (frozen-thawed transfer cycles)
Trial: 38258274
Drug: Prednisolone 5
RxNorm normalized name: prednisolone 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 5 mg
Trial: 33302704
Drug: Interpersonal and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpersonal and social rhythm therapy (with or without cognitive remediation)
Trial: 32070309
Drug: Postoperative chemoradiotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative chemoradiotherapy (POCRT) with 50.4 Gy concurrent with paclitaxel (135-150 mg/m2) plus cisplatin or nedaplatin (50-75 mg/m2) every 28 days for two cycles.
Trial: 32070309
Drug: Postoperative radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative radiotherapy (PORT) with a prescription dose of 54 Gy.
Trial: 33153439
Drug: 20 Hz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 Hz vibration therapy for 20 weeks, 9 min per day, 4 times a week
Trial: 33153439
Drug: 25 Hz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 Hz vibration therapy for 20 weeks, 9 min per day, 4 times a week
Trial: 35247334
Drug: Topical LHA510
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical LHA510 (twice a day for 8 weeks, then 3 times a day for 4 weeks)
Trial: 34346266
Drug: IND/MF high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IND/MF high-dose (150/320 μg)
Trial: 34346266
Drug: IND/MF medium-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IND/MF medium-dose (150/160 μg)
Trial: 34346266
Drug: SAL/FLU high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAL/FLU high-dose (50/500 μg)
Trial: 33755779
Drug: Regular treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular treatment and medical consultations for residents with Parkinson's disease
Trial: 35277011
Drug: RLX2™ containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RLX2™ containing alpha‐s1‐casein tryptic hydrolysate and L‐theanine
Trial: 33278754
Drug: Routine care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine care and treatment practices without family presence
Trial: 34780993
Drug: Physical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical placebo administered to the own, physical body
Trial: 33631102
Drug: Microbial Ecosystem
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Microbial Ecosystem Therapeutic 2 (MET‐2); initial daily treatment of 10 oral capsules for 2 days, then 3 capsules for 8 days; higher dose if recurrence: 20 capsules for 2 days, then 3 capsules for 8 days.
Trial: 35779302
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine (2 μg/kg)
Trial: 32147060
Drug: Fenugreek seed
RxNorm normalized name: FENUGREEK SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenugreek seed (FS) supplementation (5 g FS powder, 3 times a day)
Trial: 32147060
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (anti-diabetic drugs and nutritional consults)
Trial: 33347020
Drug: Aripiprazole (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (high and low doses)
Trial: 34836088
Drug: Single-dose intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose intake of 1.3 g of polyphenol-rich cocoa powder
Trial: 34836088
Drug: Daily consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily consumption of 1.3 g of polyphenol-rich cocoa powder for 28 days
Trial: 34836088
Drug: Single-dose intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose intake and sustained supplementation
Trial: 34217164
Drug: Nerve block
RxNorm normalized name: Nerve Block Tray 22g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve block therapy (Control)
Trial: 37980922
Drug: Step-up treatment
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Step-up treatment
Trial: 35860186
Drug: Lateral L-shaped
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lateral L-shaped incision approach (Control)
Trial: 34803872
Drug: Remote ischemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote ischemic conditioning (RIC) plus standard medical therapy
Trial: 33369276
Drug: Repository corticotropin
RxNorm normalized name: Repository Corticotropin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repository corticotropin injection 40 IU subcutaneously twice weekly for 15 days
Trial: 33369276
Drug: Repository corticotropin
RxNorm normalized name: Repository Corticotropin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repository corticotropin injection 80 IU subcutaneously twice weekly for 15 days
Trial: 33369276
Drug: Repository corticotropin
RxNorm normalized name: Repository Corticotropin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repository corticotropin injection 80 IU subcutaneously 3 times weekly for 15 days
Trial: 33369276
Drug: Synthetic ACTH1‐24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic ACTH1‐24 depot 0.5 mg subcutaneously for 5 days
Trial: 33369276
Drug: Synthetic ACTH1‐24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic ACTH1‐24 depot 0.75 mg subcutaneously for 5 days
Trial: 33369276
Drug: Synthetic ACTH1‐24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic ACTH1‐24 depot 1 mg subcutaneously for 5 days
Trial: 33369276
Drug: Synthetic ACTH1‐24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic ACTH1‐24 depot 1 mg intramuscularly for 5 days
Trial: 33414435
Drug: Cortisol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol (20 mg) administered orally 1 hour before exposure sessions
Trial: 33414435
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally 1 hour before exposure sessions
Trial: 32280055
Drug: 45 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 g/day of high‐amylose maize (RS2) for 12 weeks
Trial: 33517896
Drug: Inhaled high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled high molecular weight hyaluronan (HMW-HA)
Trial: 36456969
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) treatment combined with routine treatment
Trial: 36456969
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment (medication and rehabilitation)
Trial: 32737923
Drug: Insulin Lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin Lispro (LIS)
Trial: 35863836
Drug: Low-dose trimethoprim-sulfamethoxazole
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose trimethoprim-sulfamethoxazole (10 mg/kg/day of TMP)
Trial: 35863836
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care trimethoprim-sulfamethoxazole (15 mg/kg/day of TMP)
Trial: 32902647
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) during radiotherapy
Trial: 32902647
Drug: Radiotherapy without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy without androgen deprivation therapy (ADT)
Trial: 35810336
Drug: Exercise intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exercise intervention (high‐intensity interval exercise at 80% of VO2max, with 1‐minute high‐intensity intervals at 95% of VO2max, twice a week for 3 months)
Trial: 35429480
Drug: Ganaxolone (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganaxolone (maximum dose 63 mg/kg per day for patients weighing ≤28 kg or 1800 mg/day for patients weighing >28 kg)
Trial: 36418565
Drug: DHA-supplement (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-supplement (250 mg/day)
Trial: 36418565
Drug: DHA-supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-supplement
Trial: 34157024
Drug: six weekly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: six weekly group-format stroke risk reduction self-management training sessions
Trial: 34157024
Drug: enhanced treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enhanced treatment control (information on cardiovascular risk)
Trial: 32171028
Drug: Comprehensive medication
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive medication reviews (CMRs) during hospital stay
Trial: 32171028
Drug: Comprehensive medication
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive medication reviews (CMRs) post-discharge
Trial: 32171028
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no comprehensive medication reviews)
Trial: 35850961
Drug: 20-30 mg
RxNorm normalized name: vilazodone
DrugBank: Vilazodone (DB06684)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20-30 mg oral sustained-release morphine daily for 4 weeks
Trial: 33109480
Drug: Contemporary neuroscience
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Contemporary neuroscience approach (pain neuroscience education, stress management, cognition-targeted exercise therapy)
Trial: 33109480
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy (biomedically focused education, graded and active exercise therapy)
Trial: 35478103
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 50 μg misoprostol escalated to 100 μg and then to 200 μg every 4 h (max 600 μg daily)
Trial: 35478103
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: 25 μg misoprostol followed by 100 μg every 4 h (max 300 μg daily)
Trial: 36137672
Drug: Abbreviated antiplatelet
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abbreviated antiplatelet therapy (APT) regimen (DAPT stopped and 11 months single APT or 5 months in patients with oral anticoagulants)
Trial: 36137672
Drug: Abbreviated antiplatelet
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abbreviated antiplatelet therapy (APT) regimen
Trial: 36137672
Drug: Nonabbreviated antiplatelet
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonabbreviated antiplatelet therapy (APT) regimen (DAPT for minimum 3 months)
Trial: 33422431
Drug: Traditional medical
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional medical treatment (Control)
Trial: 34578811
Drug: 2 g/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/L dipeptide (alanyl‐glutamine)‐electrolytes (AG + E)
Trial: 35446628
Drug: ADT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADT plus orteronel (300 mg oral twice daily)
Trial: 35446628
Drug: ADT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADT with bicalutamide (50 mg oral once daily)
Trial: 34126270
Drug: LAAO with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAAO with same-day discharge and early cessation of antithrombotic therapy
Trial: 35691258
Drug: Pistacia atlantica
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pistacia atlantica subsp. Kurdica herbal capsule for 2 months
Trial: 35691258
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule for 2 months
Trial: 33722477
Drug: Individualized follitropin
RxNorm normalized name: FOLLITROPIN
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Individualized follitropin delta dosing (AMH <15 pmol/l: 12 µg/day; AMH ≥15 pmol/l: 0.10–0.19 µg/kg/day; minimum 6 µg/day; maximum 12 µg/day)
Trial: 33722477
Drug: Conventional follitropin
RxNorm normalized name: FOLLITROPIN
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Conventional follitropin beta dosing (150 IU/day for the first 5 days, with potential subsequent dose adjustments)
Trial: 33790400
Drug: Isometric exercises
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isometric exercises (maximum clenching for 10 seconds, repeated five times, twice daily for 4 weeks)
Trial: 33790400
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (tapping teeth at arbitrary speed for 10 seconds, repeated five times, twice daily for 4 weeks)
Trial: 33491582
Drug: Paracetamol (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (1.5 g)
Trial: 33491582
Drug: Tramadol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (100 mg) and Paracetamol (1.5 g)
Trial: 36199120
Drug: Problem-solving therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-solving therapy (PST) plus BEACON smartphone application
Trial: 36199120
Drug: Problem-solving therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-solving therapy (PST) alone
Trial: 34759989
Drug: Apple syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apple syrup (Malus domestica), administered three times a day along with antiemetic treatment and chemotherapy
Trial: 33144461
Drug: Negative Pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative Pressure Wound Therapy (NPWT) using the PICO™ device
Trial: 34252252
Drug: Tacrolimus 0.1%
RxNorm normalized name: TACROLIMUS 0.1% OINT,TOP
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus 0.1% ointment (T group)
Trial: 32205226
Drug: Lusutrombopag (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lusutrombopag (3 mg) daily for 7 days before the invasive procedure
Trial: 34581270
Drug: Tamoxifen 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 300 mg/day
Trial: 34334142
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care intervention by a pharmacist trained in motivational interviewing
Trial: 35878584
Drug: Antidepressants treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants treatment (specifics not provided)
Trial: 32632450
Drug: EOC: 44.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EOC: 44.1 mg/kg CS
Trial: 32632450
Drug: MON: 50.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MON: 50.8 mg/kg CS
Trial: 35501519
Drug: 755-nm picosecond
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 755-nm picosecond alexandrite laser with topical tranexamic acid (TTA) combination therapy
Trial: 33482902
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose of intravenous hAF (in the last 6 patients)
Trial: 32440816
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids at a daily dose of 1000 mg for 30 days
Trial: 34006508
Drug: Subretinal AAV8.CNGA3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subretinal AAV8.CNGA3 gene therapy
Trial: 34030027
Drug: Buprenorphine (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (administered two hours before assessment)
Trial: 35610642
Drug: Intra-articular hyaluronan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular hyaluronan (HA) injections
Trial: 34404045
Drug: Herbal oil
RxNorm normalized name: MENTHOL 3.5 g in 100 mL TOPICAL OIL [Double Prawn Brand Herbal Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal oil cream
Trial: 36075246
Drug: Evolocumab 420
RxNorm normalized name: evolocumab 420 in 3.5 ML Cartridge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab 420 mg monthly with background statins with or without ezetimibe for 80 weeks
Trial: 34810387
Drug: Antioxidant therapy
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant therapy containing natural lycopene with green tea extract
Trial: 36099282
Drug: Personalized biological
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized biological feedback related to physical activity behaviors
Trial: 34202314
Drug: Duloxetine 30
RxNorm normalized name: duloxetine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 30 mg once a day
Trial: 34495340
Drug: Extended-Release Buprenorphine
RxNorm normalized name: Buprenorphine Extended-Release Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-Release Buprenorphine (XRB)